ANVS Annovis Bio, Inc.

NYSE
$0.71

Annovis Bio, Inc. (ANVS) is expected to report earnings on February 12, 2027, before the market open. The consensus earnings estimate is a loss of $0.21 per share, and the stock has had a Post-Earnings Announcement Drift (PEAD) of -19.6% since its last earnings release on November 13, 2026.

Annovis Bio Beat Consensus Estimates
Friday, November 13, 2026 · 8:00 AM ET
Earnings Date
4th Quarter, Dec 2026
Feb 12
Friday · 8:00 AM ET
Earnings Whisper
-
vs ($0.21)
Volatility
Enter your expectations below to reveal the current volatility.
Trend Analysis
Expectation
Earnings
Price action
Signals
Score
Sentiment
Grade
Life Cycle
Call Analysis
Earnings-AVWAP $0.79

Sign in or subscribe to unlock sentiment, short interest, and technical indicators.

About Annovis Bio, Inc.

Annovis Bio Inc. is a clinical-stage, drug platform company addressing neurodegeneration, such as Alzheimer's disease, Parkinson's disease and Alzheimer's in Down Syndrome. Annovis Bio Inc. is headquartered in Berwyn, Pennsylvania.

Sector

Healthcare

Industry

Biotechnology

Charts powered in part by Lightweight Charts™ by TradingView.